Compare · FLXN vs RTRX
FLXN vs RTRX
Side-by-side comparison of Flexion Therapeutics, Inc. (FLXN) and Retrophin, Inc. (RTRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLXN and RTRX operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN carries a market cap of $458.9M.
- FLXN has more recent analyst coverage (7 ratings vs 0 for RTRX).
- Company
- Flexion Therapeutics, Inc.
- Retrophin, Inc.
- Price
- $25.60+0.16%
- -
- Market cap
- $458.9M
- -
- 1M return
- +2.03%
- -
- 1Y return
- +0.35%
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 7
- 0
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)
Latest RTRX
- Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
- Retrophin Completes Acquisition of Orphan Technologies
- Retrophin to Present at Upcoming Investor Conferences
- Retrophin Reports Third Quarter 2020 Financial Results
- Retrophin Announces Agreement to Acquire Orphan Technologies
- Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined